[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aortic-stenosis-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aortic-stenosis-disease":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,38,65,99,130,155,186],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100580166","clinical-and-cpet-parameters-that-predict-improvement-in-functional-capacity-after-tavi-100580166",false,"NCT06833762","Clinical and CPET Parameters That Predict Improvement in Functional Capacity After TAVI","Determining Clinical and Cardiopulmonary Exercise Testing Parameters That Predict Improvement in Functional Capacity and Complications After Transcatheter Aortic Valve Implantation","Inclusion Criteria:\n\n* All those patients ≥ 18 years of age with severe aortic stenosis approved for transfemoral TAVI.\n\nBoth sexes, male and female will be included in the study.\n\nExclusion Criteria:\n\nVery severe aortic stenosis, defined as a valve area of ≤0.6 cm2\n\n, mean gradient ≥60 mmHg or Vmax \\>5 m\u002Fs\n\n* Previous syncope\n* Proven exercise-induced arrhythmias\n* Previously known dynamic left ventricular outflow tract (LVOT) obstruction, defined as LVOT gradient of ≥ 30 mmHg by echocardiography\n* Concomitant coronary artery disease pending percutaneous coronary intervention\n* Inability to consent\n* Physical limitation to perform an exercise test\n* Non-elective procedure\n* Valve-in-valve procedure","ALL","18 Years",{"count":19,"type":20},161,"ESTIMATED","OBSERVATIONAL","Determining Clinical and Cardiopulmonary exercise testing Parameters that may predict Improvement in Capacity After Transcatheter Aortic Valve Implantation",[24],"Aortic Stenosis Disease","RECRUITING","2026-06-17",{"date":28,"type":29},"2026-06-22","ACTUAL",{"date":31,"type":29},"2025-01-01",{"date":33,"type":20},"2026-07",{"name":35,"class":36},"Hospital Clinic of Barcelona","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":48,"conditions":49,"keywords":50,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100582482","aortic-stenosis---prognosis-risk-and-outcomes-100582482","NCT06863883","Aortic Stenosis - Prognosis, Risk and Outcomes","Measuring Outcomes in Aortic STenosis Patients Undergoing AVR - Evaluation of Prognosis Regarding Short- and Long-term Results (MASTER)","MASTER","Inclusion Criteria:\n\n* Patient with clinical indication for aortic valve replacement and scheduled for TAVI\n* Patient willing and able to provide signed informed consent\n\nExclusion Criteria:\n\n* Inability to provide informed consent Additional exclusion criteria for MRI\n* Estimated glomerular filtration rate \\\u003C30 ml\u002Fkg\u002Fmin (MRI without contrast can be performed )\n* Claustrophobia or inability to tolerate confined spaces.\n* Non-compatible metal device present in body\n* Any other contra-indications for MRI as per local guidelines Additional exclusion criteria for the CT substudy\n* Estimated glomerular filtration rate \\\u003C30 ml\u002Fkg\u002Fmin (CT without contrast can be performed)",{"count":47,"type":20},300,"The investigators will prospectively enroll 300 patients undergoing TAVI at Sahlgrenska University Hospital, which is the second largest TAVI hospital in Sweden. Eligible patients should have a clinical indication for aortic valve replacement with TAVI and have preprocedural clinical investigations with echocardiography (UCG) and CCT and provide written informed consent. UCG, electrocardiogram (ECG) and blood samples will be taken in addition to clinical status, NYHA-class and collection of outcome events the day before the procedure, 1±2 hours, 24 ±6hours and daily after the procedure until discharged from Sahlgrenska. Further follow-up will be scheduled day 14, 30, 180, 365 and yearly. Cardiac MRI will be performed before, at 14 days and at 180 days after TAVI. Brain MRI will be performed before and 24± hours after TAVI. Cardiac CT will be performed at 180 days after TAVI.",[24],[51,52,53],"TAVI","Cardiac remodelling","Aortic stenosis","2026-05-28",{"date":56,"type":29},"2026-06-02",{"date":58,"type":29},"2025-03-04",{"date":60,"type":20},"2031-06",{"name":62,"class":63},"Vastra Gotaland Region","OTHER_GOV",2,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":73,"targetDuration":75,"studyType":21,"phases":4,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":37},"100625305","study-of-the-progression-of-chronic-cardiovascular-conditions-100625305","NCT07420907","Study of the Progression of Chronic Cardiovascular Conditions","A Non-interventional Observational Study of the Sustained Use of Prolaio Digital Health Devices to Monitor the Natural History of Chronic Cardiovascular Conditions in Ambulatory Patients","OCORO","Inclusion Criteria:\n\n* 18 years of age and older\n* Ability to understand study assessments and give informed consent to data collection\n* Ability to comply with the study protocol\n* Ability to understand and respond to instructions in English\n* Has diagnosis of qualifying Cardiovascular Disease(s) (CVD) including but not limited to: HF, AS, HCM, HTN, DCM, etc.\n* Resides in the United States\n\nExclusion Criteria:\n\n* Allergy to adhesive used in biosensor patch\n* Life threatening disease process outside of area under study, such as actively treated cancer or pre\u002Fpost-transplant such as hepatic failure; end-stage renal disease.\n* Severe CVD defined by hospital admission for cardiac diagnosis within 30 days of enrollment or documentation of NYHA functional class IV\n* Self-reported weight of 400 pounds or greater",{"count":74,"type":20},5000,"5 Years","This study will collect physiologic data in patients with cardiovascular conditions and observe the natural history of those conditions for research purposes.",[78,79,80,24,81,82,83,84,85,86,87,88],"Cardiovascular Disease (CVD)","Heart Failure","Aortic Stenosis","Hypertension","Hypertension (HTN)","Hypertrophic Cardiomyopathy Patients","Hypertrophic Cardiomyopathy Without Obstruction","Hypertrophic Cardiomyopathy, Obstructive","Dilated Cardiomyopathy (DCM)","Dilated Cardiomyopathy","Dilated Cardiomyopathy, Familial","2026-02-16",{"date":91,"type":29},"2026-02-19",{"date":93,"type":29},"2025-10-30",{"date":95,"type":20},"2030-10",{"name":97,"class":98},"Prolaio","INDUSTRY",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100596213","optimized-expansion-of-the-implanted-transcatheter-aortic-valve-100596213","NCT07042529","Optimized Expansion of the Implanted Transcatheter Aortic Valve","Optimized Expansion of the Implanted Transcatheter Aortic Valve to Reduce Hypoattenuating Leaflet Thickening in Non-atrial Fibrillation Patients Undergoing Transcatheter Aortic Valve Implantation: an International, Multicentre, Randomized Controlled Trial","OptEx-TAVI","Inclusion Criteria:\n\n* Severe symptomatic aortic stenosis patients with an indication for TAVI\n* Ability to understand and to comply with the study protocol\n\nExclusion Criteria:\n\n* Existing indication for oral anticoagulation (e.g., atrial fibrillation, venous thromboembolism, antiphospholipid syndrome, mechanical mitral valve)\n* Creatinine clearance \\\u003C15 mL\u002Fmin (CKD-EPI formula) or on renal replacement therapy\n* Iodine contrast allergy or other condition that prohibits cardiac CT imaging",{"count":108,"type":20},620,"INTERVENTIONAL",[111],"NA","Optimized Expansion of the implanted transcatheter aortic valve to reduce hypoattenuating leaflet thickening in non-atrial fibrillation patients undergoing transcatheter aortic valve implantation (TAVI): an international, multicentre, randomized controlled trial.\n\nThe objective is to evaluate whether TAVI with systematic optimized pre- and post-dilatation (optimized expansion (OptEx) TAVI strategy), compared to a standard of care (SoC) TAVI strategy, is superior in reducing hypoattenuating leaflet thickening as evaluated by cardiac computed tomography (CT) imaging at three months after TAVI.\n\nThe primary outcome is at least one thickened TAV leaflet involving ≥ 25% of the leaflet curvilinear dimension as assessed at cardiac CT at three months after TAVI.",[24,114],"Valvular Heart Disease",[53,116,117,118,119,51],"Cardiovascular","Transcatheter aortic valve","Transcatheter aortic valve implantation","Valvular heart disease","2026-02-01",{"date":122,"type":29},"2026-02-03",{"date":124,"type":29},"2025-10-05",{"date":126,"type":20},"2033-07-01",{"name":128,"class":36},"Ole De Backer",10,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":137,"sex":16,"minAge":17,"maxAge":138,"enrollmentInfo":139,"targetDuration":141,"studyType":21,"phases":4,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":37},"100619900","noninvasive-real-time-arterial-waveform-monitoring-for-cardiovascular-disease-assessment-100619900","NCT07350629","Noninvasive Real-Time Arterial Waveform Monitoring for Cardiovascular Disease Assessment","A Study on Noninvasive Real-Time Arterial Pressure Waveform Analysis for the Detection and Evaluation of Cardiovascular Diseases","Inclusion Criteria:\n\n* Age 18-80 years\n* Able to provide informed consent\n* For AR group: clinically diagnosed aortic regurgitation\n* For AS group: clinically diagnosed aortic stenosis\n* For healthy controls: no history of cardiovascular disease\n* Able to undergo finger arterial waveform measurement\n\nExclusion Criteria:\n\n* History of recent cardiac surgery or intervention (\\\u003C6 months)\n* Hand disorders affecting finger mobility (e.g., arthritis)\n* Pregnant or breastfeeding women\n* Participation in other studies affecting arterial waveform\n* Unable to understand or comply with study procedures",true,"80 Years",{"count":140,"type":20},15,"1 Day","The goal of this observational study is to learn whether noninvasive real-time arterial waveform monitoring can be used to assess cardiovascular diseases in adults. The main question it aims to answer is:\n\nCan photoacoustic imaging accurately capture arterial waveforms from patients' fingers? Can features extracted from the arterial waveforms reflect the type and severity of cardiovascular diseases? Participants will be asked to place their fingers into the imaging device, where their finger arterial pulse information will be noninvasively recorded.",[144,24,145],"Aortic Regurgitation Disease","Healthy Subjects","2026-01-11",{"date":148,"type":29},"2026-01-20",{"date":150,"type":29},"2025-12-26",{"date":152,"type":20},"2026-02",{"name":154,"class":36},"Anhui Provincial Cancer Hospital",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":109,"phases":165,"briefSummary":166,"conditions":167,"keywords":171,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":37},"100594234","cerebral-regional-oxygen-saturation-during-tavi---the-cros-tavi-prospective-registry-100594234","NCT07016789","Cerebral Regional Oxygen Saturation During TAVI - The CROS-TAVI Prospective Registry","Cerebral Regional Oxygen Saturation During TAVI: A Prospective Comparison of Balloon-Expandable and Self-Expanding Valves","CROS-TAVI","Inclusion Criteria:\n\nSigned informed consent prior to any study-specific procedures\n\nDiagnosis of severe degenerative aortic valve stenosis with echocardiographic criteria:\n\nMean gradient \\> 40 mm Hg, or\n\nJet velocity \\> 4.0 m\u002Fs, or\n\nAortic valve area (AVA) \\\u003C 0.8 cm² (or AVA index \\\u003C 0.5 cm²\u002Fm²)\n\nSymptomatic aortic stenosis defined as NYHA functional class ≥ II\n\nExclusion Criteria:\n\nSymptomatic carotid artery disease or indication for carotid revascularization\n\nCardiogenic shock or inotropic support required prior to the procedure\n\nActive neurodegenerative disease\n\nContraindications as determined by anesthesiology screening\n\nAge \\\u003C 18 years\n\nContraindications to NIRS monitoring\n\nST-elevation myocardial infarction or cardiogenic shock within 48h before enrollment\n\nEmergency TAVI due to decompensated AV stenosis\n\nMalignancy or comorbidities with life expectancy \\\u003C 12 months\n\nInability to comply with the study protocol\n\nStroke or transient ischemic attack within 6 months\n\nRenal insufficiency (creatinine \\> 3.0 mg\u002FdL) or dialysis dependency\n\nSevere left ventricular dysfunction (LVEF \\\u003C 30%)\n\nSignificant mixed valvular disease (e.g., severe mitral or tricuspid regurgitation)\n\nIntracardiac mass, thrombus, or vegetation\n\nChronic corticosteroid use\n\nParticipation in another investigational drug or device study\n\nActive bacterial endocarditis or other active infections",{"count":164,"type":20},40,[111],"This single-center, non-commercial clinical study investigates how different types of transcatheter aortic valve prostheses affect cerebral oxygen saturation during the procedure (TAVI - Transcatheter Aortic Valve Implantation). The study uses a non-invasive monitoring system (NIRS) to track brain oxygenation (rSO₂) in real time.\n\nThe goal is to understand whether balloon-expandable, intra-annular self-expanding, or supra-annular self-expanding valves lead to different levels or patterns of cerebral oxygenation. This may help identify early warning signs for delayed hemodynamic recovery, stroke, or delirium.\n\nParticipants will be randomly assigned to receive one of:\n\nA balloon-expandable valve (Group A), or\n\nA self-expanding valve (Group B), with further randomization into:\n\nGroup B1: intra-annular valve (NAVITOR)\n\nGroup B2: supra-annular valve (EVOLUT)\n\nThe procedure, follow-up, and data collection will follow standard clinical practice. No experimental devices or drugs are used. Patients will not undergo any additional risk or burden beyond what is normally expected during TAVI.\n\nThe study is being conducted at the Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome, Italy, and aims to enroll 40 patients. No compensation is provided, and participation is voluntary.",[24,168,169,170],"TAVI(Transcatheter Aortic Valve Implantation)","Cerebral Oxygen Saturation","Hemodynamic Changes",[51,172,169,173,174,175],"Aortic Valve Stenosis","NIRS","Balloon-Expandable Valve","Self-Expanding Valve","NOT_YET_RECRUITING","2025-06-23",{"date":179,"type":29},"2025-06-26",{"date":181,"type":20},"2025-06",{"date":183,"type":20},"2026-06",{"name":185,"class":36},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":109,"phases":196,"briefSummary":197,"conditions":198,"keywords":199,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":37},"100570391","impact-of-enhanced-information-on-subjective-information-level-and-proms-in-patients-with-aortic-stenosis-100570391","NCT06706635","Impact of Enhanced Information on Subjective Information Level and PROMs in Patients with Aortic Stenosis","Impact of Enhanced Information Provision by Using a Mobile App on Subjective Information Level As the Basis for Shared-decision Making and Patient-reported Outcome Measures (PROMs) in Patients with Aortic Stenosis","TAVI-SDM-APP","Inclusion Criteria:\n\n* severe aortic valve stenosis\n* planned aortic valve replacement (TAVI)\n* Patient is willing and able to complete the surveys in German language\n* Written informed consent by the trial subject\n\nExclusion Criteria:\n\n\\- Language barrier",{"count":195,"type":20},250,[111],"The aim of this trial is to evaluate if an enhanced information by using a mobile App can increase subjective information level in patients with severe aortic stenosis and may therefore improve patient-reported outcomes.",[24],[200,201],"aortic stenosis","mobile app","2024-11-22",{"date":204,"type":29},"2024-11-26",{"date":206,"type":29},"2024-08-21",{"date":208,"type":20},"2025-12",{"name":210,"class":36},"Heart and Diabetes Center North-Rhine Westfalia"]